Vaccine and Cerebral Venous Sinus Thrombosis with Thrombocytopenia – Update for Clinicians on Early Detection and Treatment

Thursday, April 15, 2-3PM EDT

Advanced registration is not required.

This COCA Call will present the latest evidence on cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated with the administration of the Johnson & Johnson/Janssen COVID-19 vaccine. Speakers will discuss what is known about CVST, the importance of early detection, and updated vaccine recommendations.

If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.

The slide set will be available under “Call Materials” on the COCA Call webpage the day of the call.

Continuing Education (CE) will not be provided for this call.


Login Information

A few minutes before the webinar starts, please click on the Zoom link to join

Or iPhone one-tap: 

US: +16692545252,,1614336614#,,,,*160026# 

or +16468287666,,1614336614#,,,,*160026#

Or Telephone: Dial (for higher quality, dial a number based on your current location): 

US +1 669 254 5252 or

+1 646 828 7666 or

+1 551 285 1373 or

+1 669 216 1590

Webinar ID: 161 433 6614

Passcode:160026

International numbers available: https://www.zoomgov.com/u/acVEZz9i4e


Learning Objectives

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.

Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Presenters

Sara Oliver, MD
LCDR, U.S. Public Health Service
Co-lead, Advisory Committee for Immunization Practices COVID-19 Vaccines Work Group
COVID-19 Response
Centers for Disease Control and Prevention

Tom Shimabukuro, MD, MPH, MBA
CAPT, U.S. Public Health Service
Vaccine Safety Team Lead
COVID-19 Response
Centers for Disease Control and Prevention

The Emergency Risk Communication Branch in the Division of Emergency Operations, Center for Preparedness and Response is responsible for the management of all COCA products.

For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov